Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weierkang vs teprenone + folic acid in chronic atrophic gastritis
ChiCTR-IPR-16010291Phase 4Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Oct 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of weierkang, teprenone and folic acid in atrophic gastritis (AG) (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Total effective rate. Started Oct 2016; status: recruiting.
02
Drugs
weierkangteprenonefolic acid
03
Conditions
atrophic gastritis (AG)
Beyond the preview
Go deeper on ChiCTR-IPR-16010291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16010291.